Hidradenitis Suppurativa and Smoking, Obesity, Psoriasis, Inflammatory Bowel Disease, and Systemic Sclerosis: Results From A 2-Sample Mendelian Randomization Study

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Psoriasis

Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study

Ann Dermatol Venereol

Aubin F, Wierzbicka-Hainaut E, Vidal M, Najean M, Begon E

doi: 10.1016/j.annder.2025.103427

Systemic Sclerosis

Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in systemic sclerosis: a real-world national cohort study

Rheumatology (Oxford)

Keret S, Yaari S, Shouval A, Sawaed A, Nemesh N, Kaly L, Awisat A, Rosner I, Rozenbaum M, Boulman N, Hardak E, Slobodin G, Rimar D

doi: 10.1093/rheumatology/keaf664

Systemic Sclerosis

Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study

Arthritis Res Ther

Hiura R, Ayano M, Uchino A, Hiura J, Ueda N, Tanaka A, Yoshizawa S, Kawano S, Sagawa F, Ota SI, Hirata A, Fujimoto S, Nishimura N, Takaki-Kuwahara A, Kimoto Y, Akashi K, Niiro H

doi: 10.1186/s13075-025-03654-0

Acne

Neighborhood Socioeconomic Status and New Hidradenitis Suppurativa Diagnoses in a Single Health System

JAMA Dermatol

Chang AY, Sanchez-Anguiano ME, Supapannachart K, Amerson EH, Naik HB, Shiboski S, Derouen MC, Yazdany J

doi: 10.1001/jamadermatol.2025.1190

Psoriasis

Low-grade systemic inflammation is associated with risk of psoriasis in a general population study of more than 100,000 individuals

Br J Dermatol

Näslund-Koch C, Kvist-Hansen A, Bojesen SE, Skov L, Kobylecki CJ, Vedel-Krogh S

doi: 10.1093/bjd/ljaf147

Acne

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II

J Eur Acad Dermatol Venereol

Tzellos T, Giamarellos-Bourboulis EJ, van Straalen KR, Martorell A, Kirby B, Alavi A, Hayama K, Khattri S, Gulliver W, Sayed CJ, Davis L, Rolleri RL, Crater C, Pansar I, Lambert J, Zouboulis CC

doi: 10.1111/jdv.70356

Related content

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Clinical characteristics, disease burden, and unmet medical needs of generalized pustular psoriasis: Results of the SCRIPTOR study

Neutrophil-to-lymphocyte ratio as a biomarker for disease onset and mortality risk in systemic sclerosis: a real-world national cohort study

Efficacy and safety of rituximab versus intravenous cyclophosphamide for systemic sclerosis-associated interstitial lung disease: a retrospective cohort study

Neighborhood Socioeconomic Status and New Hidradenitis Suppurativa Diagnoses in a Single Health System

Low-grade systemic inflammation is associated with risk of psoriasis in a general population study of more than 100,000 individuals

Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II